Considering the effectiveness of TCZ—even as monotherapy without MTX, regardless of anti-Ro/SS-A antibody status, along with its lower association with the onset of LPD—it appears to be a promising option for treating patients with RA and sSS and/or positive for anti-Ro/SS-A antibodies. This evidence concerns the gene RO60 and rheumatoid arthritis.